MDNAF
Price
$0.79
Change
-$0.01 (-1.25%)
Updated
Aug 22 closing price
Capitalization
66.13M
83 days until earnings call
STOK
Price
$19.56
Change
-$0.12 (-0.61%)
Updated
Aug 22 closing price
Capitalization
1.07B
79 days until earnings call
Interact to see
Advertisement

MDNAF vs STOK

Header iconMDNAF vs STOK Comparison
Open Charts MDNAF vs STOKBanner chart's image
Medicenna Therapeutics
Price$0.79
Change-$0.01 (-1.25%)
Volume$29.62K
Capitalization66.13M
Stoke Therapeutics
Price$19.56
Change-$0.12 (-0.61%)
Volume$1.15M
Capitalization1.07B
MDNAF vs STOK Comparison Chart in %
Loading...
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDNAF vs. STOK commentary
Aug 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDNAF is a StrongBuy and STOK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 24, 2025
Stock price -- (MDNAF: $0.79 vs. STOK: $19.56)
Brand notoriety: MDNAF and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDNAF: 71% vs. STOK: 142%
Market capitalization -- MDNAF: $66.13M vs. STOK: $1.07B
MDNAF [@Biotechnology] is valued at $66.13M. STOK’s [@Biotechnology] market capitalization is $1.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.31B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDNAF’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • MDNAF’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than MDNAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDNAF’s TA Score shows that 5 TA indicator(s) are bullish while STOK’s TA Score has 4 bullish TA indicator(s).

  • MDNAF’s TA Score: 5 bullish, 5 bearish.
  • STOK’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both MDNAF and STOK are a good buy in the short-term.

Price Growth

MDNAF (@Biotechnology) experienced а +3.69% price change this week, while STOK (@Biotechnology) price change was +7.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.57%. For the same industry, the average monthly price growth was +18.06%, and the average quarterly price growth was +26.94%.

Reported Earning Dates

MDNAF is expected to report earnings on Nov 14, 2025.

STOK is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($1.07B) has a higher market cap than MDNAF($66.1M). STOK YTD gains are higher at: 77.335 vs. MDNAF (-30.873). STOK has higher annual earnings (EBITDA): 42.3M vs. MDNAF (-21.81M). STOK has more cash in the bank: 248M vs. MDNAF (20.5M). MDNAF has less debt than STOK: MDNAF (162K) vs STOK (2.3M). STOK has higher revenues than MDNAF: STOK (200M) vs MDNAF (0).
MDNAFSTOKMDNAF / STOK
Capitalization66.1M1.07B6%
EBITDA-21.81M42.3M-52%
Gain YTD-30.87377.335-40%
P/E RatioN/A22.48-
Revenue0200M-
Total Cash20.5M248M8%
Total Debt162K2.3M7%
FUNDAMENTALS RATINGS
MDNAF vs STOK: Fundamental Ratings
MDNAF
STOK
OUTLOOK RATING
1..100
1723
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9846
PRICE GROWTH RATING
1..100
4735
P/E GROWTH RATING
1..100
10011
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDNAF's Valuation (49) in the null industry is in the same range as STOK (59). This means that MDNAF’s stock grew similarly to STOK’s over the last 12 months.

MDNAF's Profit vs Risk Rating (100) in the null industry is in the same range as STOK (100). This means that MDNAF’s stock grew similarly to STOK’s over the last 12 months.

STOK's SMR Rating (46) in the null industry is somewhat better than the same rating for MDNAF (98). This means that STOK’s stock grew somewhat faster than MDNAF’s over the last 12 months.

STOK's Price Growth Rating (35) in the null industry is in the same range as MDNAF (47). This means that STOK’s stock grew similarly to MDNAF’s over the last 12 months.

STOK's P/E Growth Rating (11) in the null industry is significantly better than the same rating for MDNAF (100). This means that STOK’s stock grew significantly faster than MDNAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDNAFSTOK
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 26 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
MDNAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HDPMX82.392.44
+3.05%
Hodges Retail
FVLTX21.060.41
+1.99%
Fidelity Advisor Value Leaders M
LGLAX53.900.82
+1.54%
Lord Abbett Growth Leaders A
FHLFX14.890.22
+1.50%
Fidelity Series International Index
NRAEX52.820.65
+1.25%
Neuberger Berman Quality Equity E

MDNAF and

Correlation & Price change

A.I.dvisor tells us that MDNAF and LRMR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDNAF and LRMR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDNAF
1D Price
Change %
MDNAF100%
-1.06%
LRMR - MDNAF
25%
Poorly correlated
+5.96%
VIR - MDNAF
25%
Poorly correlated
+4.57%
STOK - MDNAF
23%
Poorly correlated
-0.61%
CGEM - MDNAF
23%
Poorly correlated
+6.78%
PTCT - MDNAF
22%
Poorly correlated
+3.37%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
-0.61%
IDYA - STOK
50%
Loosely correlated
+1.99%
QTTB - STOK
49%
Loosely correlated
+1.87%
SYRE - STOK
47%
Loosely correlated
+3.58%
IMNM - STOK
47%
Loosely correlated
+3.52%
DNLI - STOK
47%
Loosely correlated
+1.71%
More